glp-1 adoption drugs are rewriting America's food preferences, says IFF GLP-1s in 2025: Who's Using

Obes Facts (2015) 8:40224

Phase 2 trial dosing groups explained The trial randomized participants into seven groups

The FDA notes it has collected reports of compounded GLP-1s not being refrigerated adequately or being made with poor-quality ingredients

A portion of those who start on the drugs discontinue their use, and among these people, food purchases rebound

GLP-1 Trends: Ozempic and Semaglutide drive a 587% spike in prescriptions Prescriptions for GLP-1 receptor agonists, including Ozempic, Semaglutide, and Rybelsus, have surged over the last five years as their effectiveness in promoting weight loss gains attention beyond type 2 diabetes care

[17] Yet, at the same time, GLP-1s appeared to protect against late-stage retinopathy when compared with insulin